Generate Biomedicines (NASDAQ:GENB) Releases Earnings Results, Misses Estimates By $0.59 EPS

Generate Biomedicines (NASDAQ:GENB) released its earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59), Zacks reports.

Generate Biomedicines Stock Up 0.5%

GENB stock traded up $0.07 during mid-day trading on Friday, hitting $13.66. The company had a trading volume of 291,612 shares, compared to its average volume of 465,861. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $15.89. The firm’s 50-day moving average price is $12.62.

Analysts Set New Price Targets

A number of research firms recently weighed in on GENB. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Piper Sandler initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.00.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.